论文部分内容阅读
一、淋巴因子免疫疗法最近,重组淋巴因子的克隆、表达和大规模制备大大促进了辅助性T 细胞依赖性效应细胞的开发应用。尤其是重组IL-2已在体外用于诱导LAK 细胞,且能使转移性恶性黑色素瘤、肾细胞癌等某些肿瘤得以缓解。IL-2扩增后的TILS(肿瘤侵润性淋巴细胞),包括LAK 细胞前体、细胞毒性T 细胞和辅助性T 细胞,对同系肿瘤明显具有比LKA 细胞更强的细胞毒性,从而具有更大的疗效潜力。很多淋巴因子,包括IL-1、LL-4、IL-5、TNF、GM-CSF 和IFN—β在体外诱导LAK 细胞中与IL-2有协同作用,从而为淋巴因子联合应用的体内试验开
I. Lymphokine immunotherapy Recently, the cloning, expression and large-scale preparation of recombinant lymphokines have greatly facilitated the development and application of helper T cell-dependent effector cells. In particular, recombinant IL-2 has been used to induce LAK cells in vitro, and can relieve metastatic malignant melanoma, renal cell carcinoma and some other tumors. TILS (tumor infiltrating lymphocytes) after IL-2 expansion, including LAK cell precursors, cytotoxic T cells, and helper T cells, clearly have more cytotoxicity than LKA cells against syngeneic tumors, resulting in more Great therapeutic potential. Many lymphokines, including IL-1, LL-4, IL-5, TNF, GM-CSF, and IFN-β, synergize with IL-2 in inducing LAK cells in vitro, thereby opening up in vivo trials for the combined use of lymphokines.